p-tau biomarker_for Alzheimer's disease
Evidence from:
primary |
all sources
Evidence (3 sources)
Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector.
(2018)
PMID:29632371
cited
As in AD brains, p-tau also mislocalized to dendrites of apoE4/4-GABAergic neurons
confidence: 0.92
Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector.
(2018)
PMID:29632371
cited
As in AD brains, p‑tau also accumulates, indicating its relevance to Alzheimer disease.
confidence: 0.85
Early pathogenic event of Alzheimer's disease documented in iPSCs from patients with PSEN1 mutations.
(2017)
PMID:27926491
cited
Aβ accumulation has been considered as a late event in AD ... changes in Aβ42 and p-tau levels.
confidence: 0.90